NCT00864318 2026-04-14
TICE
Institut Claudius Regaud
Phase 2 Completed
Clinical Trials
8 trialsNCT03458260 2026-03-10
Study of Pixantrone in CD20+ Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma
The Lymphoma Academic Research Organisation
Phase 2 Completed
NCT04154189 2024-07-22
A Study to Compare the Efficacy and Safety of Ifosfamide and Etoposide With or Without Lenvatinib in Children, Adolescents and Young Adults With Relapsed and Refractory Osteosarcoma
Eisai Inc.
Phase 2 Completed
NCT00574496 2023-09-28
Combination Chemotherapy Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or High-Risk Primary Refractory Hodgkin Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT02686346 2021-12-07
BV-ICE
The Lymphoma Academic Research Organisation
Phase 1/2 Completed
NCT00381940 2021-03-24
Bortezomib, Ifosfamide, and Vinorelbine Tartrate in Treating Young Patients With Hodgkin's Lymphoma That is Recurrent or Did Not Respond to Previous Therapy
National Cancer Institute (NCI)
Phase 2 Completed
NCT00003631 2016-01-25
Chemotherapy Plus Radiation Therapy in Treating Patients With Refractory or Relapsed Hodgkin's Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00006760 2013-07-26
Combination Chemotherapy in Treating Children With Refractory or Relapsed Hodgkin's Lymphoma
Children's Oncology Group
Phase 2 Completed